Sezer O, Niemöller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M, Possinger K
Universitätsklinikum Charite, Humboldt-Universität zu Berlin, Department of Hematology and Oncology, Germany.
Ann Hematol. 2000 Oct;79(10):574-7. doi: 10.1007/s002770000236.
The importance of neoangiogenesis for the progressive growth and viability of solid tumors is well established. Recently, there has been growing evidence that angiogenesis might also be important in hematological malignancies, but only few data are available. In this report, we have studied the impact of bone marrow microvessel density and survival in patients with multiple myeloma (MM). Immunohistochemical CD34 stained paraffin-embedded bone marrow biopsies of 44 patients with newly diagnosed MM were studied. Microvessels were counted in 400 x magnification and the mean number of vessels per area in each sample was noted as the microvessel density (MVD). The median MVD was 48 vessels/mm2, the range was 0-125 vessels/mm2. Using a cut-off value of the median MVD in the Kaplan-Meier analysis, the median survival was 22.2 months in the group with the higher MVD and was not reached in the group with the lower MVD (P< 0.01). In a multivariate Cox regression analysis, using previously identified prognostic factors beta2-microglobulin, C-reactive protein (CRP), and age, MVD remained significant as a prognostic factor (P< 0.03).
新生血管生成对于实体瘤的渐进性生长和存活的重要性已得到充分证实。最近，越来越多的证据表明血管生成在血液系统恶性肿瘤中可能也很重要，但相关数据却很少。在本报告中，我们研究了多发性骨髓瘤（MM）患者骨髓微血管密度与生存情况之间的关系。对44例新诊断MM患者的免疫组化CD34染色石蜡包埋骨髓活检标本进行了研究。在400倍放大倍数下对微血管进行计数，并将每个样本每单位面积的血管平均数记录为微血管密度（MVD）。MVD的中位数为48个血管/mm²，范围为0 - 125个血管/mm²。在Kaplan-Meier分析中，以MVD中位数作为临界值，MVD较高组的中位生存期为22.2个月，MVD较低组未达到中位生存期（P < 0.01）。在多因素Cox回归分析中，将先前确定的预后因素β2-微球蛋白、C反应蛋白（CRP）和年龄纳入分析，MVD作为预后因素仍然具有显著性（P < 0.03）。
